Pharmaceutical formulations containing HIV protease inhibitors,
specifically including
3S-[3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-
hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester
(alternatively known as VX 478 or 141W94), and a tocopherol, and their use
in medical therapy are described.
